Comparative effectiveness of <scp>anti‐IL5</scp> and <scp>anti‐IgE</scp> biologic classes in patients with severe asthma eligible for both

Abstract

In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.